Tweet Are all the anti-CD20 depleting antibodies the same? This study aims to show if rituximab is inferior to ocrelizumab, MSBase said it was. I would ask why? What biology is different?…They are clearly not all the same in how they do things but they all aim to kill circulating B cells. This study is…
Month: November 2025
Fashion, MS and a 28-year moment I’ll never forget
I never could have imagined that exactly 28 years after being diagnosed with Multiple Sclerosis, I’d find myself on a runway in Fort Lauderdale, Florida—modeling adaptive clothing, no less. And I certainly never imagined I’d be modeling adaptive clothing with my husband. But that’s exactly what happened on November 14, 2025. Just. Wow. It was…
Not all disability progression is permanent in RRMS, data suggest
Disability progression is not always permanent for people with relapsing-remitting multiple sclerosis (RRMS), even when it occurs independent of a relapse, a new study has found. Researchers report that nearly one-third of RRMS patients who experience progression independent of relapse activity (PIRA) see their disability levels ease in the years following the initial event. These…
PPI scandi Style
Tweet Patient and public involvement (PPI) has been the mantra in grant review and research funding for years. It is said that “People living with a health condition are often in a better position to know what questions remain unanswered about their treatment or condition, and what research would most likely improve their quality of…
I’ve got many things to be thankful for, but I’m not thanking MS yet
“Don’t thank me yet.” Whenever I use that phrase, I mean it in the way it’s traditionally meant. Whatever it is that you’re thanking me for isn’t complete, so wait until I’m done in case you’re not entirely thankful for the results. That’s how I’ve perceived the idiom for most of my life, but I’m…
Worsening Types
Tweet De Meo E, Addazio I, Portaccio E, Bonacchi R, Betti M, Patti F, Guerrieri S, Foschi M, Ferraro D, Annovazzi P, Brescia Morra V, Tortorella C, Lugaresi A, Camilli F, Pozzilli C, Perini P, Granella F, De Luca G, Torri Clerici VLAM, Vianello M, Romano S, Cocco EE, Lus G, Di Sapio A, Rocca…
With MS, holiday prepping is about shifting the bar, not lowering it
The holidays tend to arrive with a mix of excitement and stress, even for people without a chronic illness. But for those of us living with multiple sclerosis (MS), the season can feel like its own kind of marathon, full of expectations, overscheduling, symptoms that flare when we least want them to, and the pressure…
New MS research finds early immune activity in myelin cells
Oligodendrocytes, the cells that build and repair myelin in the brain and spinal cord, may play a role in the inflammatory processes involved in multiple sclerosis (MS), even at the earliest stages of disease, according to a study in a mouse model. “We found that oligodendrocytes transition to disease states already at early stages in…
Lower-dose contrast agent Vueway passes 3M doses
More than 3 million doses of Vueway (gadopiclenol), a lower-dose gadolinium contrast MRI agent used to diagnose and monitor conditions such as multiple sclerosis (MS), have been administered at more than 900 customer sites, maker Bracco Diagnostics said. Approved by the U.S. Food and Drug Administration for use in children and adults, ages 2 years and older,…
From our CEO
The post From our CEO appeared first on MS Australia. Source: www.msaustralia.org.au